Variceal bleeding: Pharmacological therapy

被引:14
作者
Bosch, J [1 ]
Abraldes, JG [1 ]
机构
[1] Univ Barcelona, IDIBAPS, Hosp Clin, Liver Unit,Hepat Hemodynam Lab, ES-08036 Barcelona, Spain
关键词
portal hypertension; beta-adrenergic blockers; cirrhosis;
D O I
10.1159/000084722
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The complications of portal hypertension are totally prevented if hepatic venous pressure gradient is decreased below 12 mm Hg. Besides, if this target is not achieved, a 20% decrease in portal pressure from baseline levels offers an almost total protection from variceal bleeding. This sets the rationale for drug therapy to reduce portal pressure in portal hypertension. Pharmacological therapy to decrease portal pressure includes vasoconstrictors to decrease portal blood inflow, vasodilators to decrease hepatic resistance, and combination therapy. Oral agents, such as beta-adrenergic blockers and organic nitrates, are used for long-term prevention of variceal bleeding, while parenteral agents, such as somatostatin (and analogues) and terlipressin, are used for the treatment of acute variceal bleeding. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:18 / 29
页数:12
相关论文
共 130 条
[1]   Propranolol for the prevention of first esophageal variceal hemorrhage:: A lifetime commitment? [J].
Abraczinskas, DR ;
Ookubo, R ;
Grace, ND ;
Groszmann, RJ ;
Bosch, J ;
Garcia-Tsao, G ;
Richardson, CR ;
Matloff, DS ;
Rodés, J ;
Conn, HO .
HEPATOLOGY, 2001, 34 (06) :1096-1102
[2]   Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis [J].
Abraldes, JG ;
Tarantino, I ;
Turnes, J ;
Garcia-Pagan, JC ;
Rodés, J ;
Bosch, J .
HEPATOLOGY, 2003, 37 (04) :902-908
[3]   Somatostatin and analogues in portal hypertension [J].
Abraldes, JG ;
Bosch, J .
HEPATOLOGY, 2002, 35 (06) :1305-1312
[4]   HEMODYNAMIC-EFFECTS OF ALPHA-ADRENERGIC BLOCKADE WITH PRAZOSIN IN CIRRHOTIC-PATIENTS WITH PORTAL-HYPERTENSION [J].
ALBILLOS, A ;
LLEDO, JL ;
BANARES, R ;
ROSSI, I ;
IBORRA, J ;
CALLEJA, JL ;
GARRIDO, A ;
ESCARTIN, P ;
BOSCH, J .
HEPATOLOGY, 1994, 20 (03) :611-617
[5]   CONTINUOUS PRAZOSIN ADMINISTRATION IN CIRRHOTIC-PATIENTS - EFFECTS ON PORTAL HEMODYNAMICS AND ON LIVER AND RENAL-FUNCTION [J].
ALBILLOS, A ;
LLEDO, JL ;
ROSSI, I ;
PEREZPARAMO, M ;
TABUENCA, MJ ;
BANARES, R ;
IBORRA, J ;
GARRIDO, A ;
ESCARTIN, P ;
BOSCH, J .
GASTROENTEROLOGY, 1995, 109 (04) :1257-1265
[6]   Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension [J].
Albillos, A ;
García-Pagán, JC ;
Iborra, J ;
Bandi, JC ;
Cacho, G ;
Pérez-Paramo, M ;
Escorsell, A ;
Calleja, JL ;
Escartin, P ;
Bosch, J .
GASTROENTEROLOGY, 1998, 115 (01) :116-123
[7]   Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide [J].
Angeli, P ;
Volpin, R ;
Gerunda, G ;
Craighero, R ;
Rone, P ;
Merenda, R ;
Amodio, P ;
Sticca, A ;
Caregaro, L ;
Maffei-Faccioli, A ;
Gatta, A .
HEPATOLOGY, 1999, 29 (06) :1690-1697
[8]   Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis [J].
Angelico, M ;
Carli, L ;
Piat, C ;
Gentile, S ;
Capocaccia, L .
GASTROENTEROLOGY, 1997, 113 (05) :1632-1639
[9]   Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European acute bleeding oesophageal variceal episodes (ABOVE) randomised trial [J].
Avgerinos, A ;
Nevens, F ;
Raptis, S ;
Fevery, J ;
Armonis, A ;
Manolakopoulos, S ;
Poulianos, G ;
Tzathas, C ;
Katsaros, D ;
Soutos, D ;
Zacharopoulose, A ;
Adler, M ;
Bourgeois, N ;
Bac, DJ ;
VanBuuren, HR ;
Decruyenaere, J ;
Elewaut, A ;
Deman, M ;
Lepoutre, L ;
VanderSpek, P ;
Hautekeete, M ;
Reynaert, H ;
Buyse, M ;
Ritter, L ;
Burtin, B ;
Darcis, T ;
Ioannou, J ;
Natens, J ;
Natens, O .
LANCET, 1997, 350 (9090) :1495-1499
[10]  
BALLET F, 1988, J PHARMACOL EXP THER, V244, P283